SOURCE: MagForce Nanotechnologies AG

November 18, 2010 12:01 ET

MagForce Nanotechnologies AG to Present at Deutsches Eigenkapitalforum

BERLIN, GERMANY--(Marketwire - November 18, 2010) - MagForce Nanotechnologies AG / MagForce Nanotechnologies AG to Present at Deutsches Eigenkapitalforum Processed and transmitted by Thomson Reuters. The issuer is solely responsible for the content of this announcement.

Berlin, November 18, 2010 - MagForce Nanotechnologies AG (FSE: MF6), a leader in the area of nanotechnology-based cancer treatment, announced today that Dr. Peter Heinrich, CEO, will present the latest company developments and outline plans for 2011 at the Deutsches Eigenkapitalforum. The presentation will take place on Tuesday, November 23, 2010, at 8:15 in Sector Technology (Paris Room). Earlier this year, MagForce received EU approval for its medical products, NanoTherm(®) and NanoActivator™, for the treatment of brain tumors. The company plans to launch its Nano-Cancer(®) therapy at leading cancer centers in Germany in the first quarter of 2011.

ABOUT MAGFORCE NANOTECHNOLOGIES: MagForce Nanotechnologies AG is a leader in the area of nanotechnology- based cancer treatment and the first company worldwide to receive European approval for a medical product using nanoparticles. Its proprietary procedure, Nano- Cancer(®) therapy, enables the targeted treatment of solid tumors through the intratumoral release of heat from magnetic nanoparticles. The company's products, Nanotherm(®), NanoPlan(®), and NanoActivator™ are the components of its Nano-Cancer(®) therapy.

DISCLAIMER: This release may contain forward-looking statements and information which may be identified by formulations using terms such as "expects," "aims," "anticipates," "intends," "plans," "believes," "seeks," "estimates," or "will". Such forward- looking statements are based on our current expectations and certain assumptions which may be subject to a variety of risks and uncertainties. The results actually achieved by MagForce Nanotechnologies AG may substantially differ from these forward-looking statements. MagForce Nanotechnologies AG assumes no obligation to update these forward-looking statements or to correct them in case of developments which differ from those anticipated. MagForce, Nanotherm, NanoActivator and Nano-Cancer are trademarks of MagForce Nanotechnologies AG in selected countries.

For questions, please contact:
Stacy Wiedenmann
Director, Investor Relations & Corporate Communications
Magforce Nanotechnologies AG
Max-Dohrn-Str. 8
10589 Berlin
T +49 30 308 380 31
F +49 30 308 380 99
M +49 151 12000 722
email:swiedenmann@magforce.com
www.magforce.com

[HUG#1463954]

--- End of Message ---

MagForce Nanotechnologies AG Max-Dohrn-Str. 8 Berlin Germany

Listed: Open Market (Freiverkehr) in Frankfurter Wertpapierbörse;

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: MagForce Nanotechnologies AG via Thomson Reuters ONE

Contact Information

  • For questions, please contact:
    Stacy Wiedenmann
    Director, Investor Relations & Corporate Communications
    Magforce Nanotechnologies AG
    Max-Dohrn-Str. 8
    10589 Berlin
    T +49 30 308 380 31
    F +49 30 308 380 99
    M +49 151 12000 722
    email: Email Contact
    www.magforce.com